Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Tumour Site

Urothelial Cancer

Presenters

Albert Font

Citation

Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

Authors

A. Font1, M. Domenech2, J.L. Ramirez3, J. Gago4, C. Carrato5, B. Cadenas6, R. Benítez7, T. Lobato8, S. Pineda7, V. Ruiz de Porras8, M.L. Calle9, N. Malats7, F.X. Real10

Author affiliations

  • 1 Medical Oncology Department, Institut Català d'Oncologia Badalona - B·ARGO group, 08916 - Badalona/ES
  • 2 Medical Oncology Department, Fundació Althaia, Manresa/ES
  • 3 Molecular Biology And Hematology Unit, Catalan Institute of Oncology (ICO), 08916 - Badalona/ES
  • 4 Urology Department, Hospital Universitari Germans Trias i Pujol, 08916 - Badalona/ES
  • 5 Pathology Department, Hospital Universitari Germans Trias i Pujol, 08916 - Badalona/ES
  • 6 Experimental Sciences And Technology, Universitat de Vic-Universitat Central de Catalunya, Vic/ES
  • 7 Genetic And Molecular Epidemiology Group, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid/ES
  • 8 Urologic Tumors Unit; Badalona-applied Research Group In Oncology (b·argo), Germans Trias i Pujol Research Institute, 08916 - Badalona/ES
  • 9 Biosciences Department, Faculty Of Science And Technologys, Universitat de Vic-Universitat Central de Catalunya, Vic/ES
  • 10 Molecular Oncology Programme, Centro Nacional de Investigaciones Oncologicas (CNIO), 28029 - Madrid/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5211

Background

Neoadjuvant chemotherapy (NAC) followed by cystectomy is the standard of care in MIBC patients, although a limited survival benefit has been obtained compared with cystectomy alone. Pathologic response has been associated with survival, but, unfortunately, neither baseline clinical or pathological variables have demonstrated ability to predict which patients will benefit from NAC, pointing to the need of predictive biomarkers of NAC response to guide treatment decisions. The objective of this retrospective study was to identify a NAC response prediction signature integrating baseline clinical features, taxonomic subtypes, and RNA expression profile in MIBC patients.

Methods

Formalin-fixed paraffin-embedded pre-treatment tumor samples were collected by transurethral resection from 112 patients with MIBC stage T2-4N0/+M0 treated with NAC followed by cystectomy. Immunohistochemical-based taxonomic subtypes (BASQ-like, luminal-like, mixed) were established. Gene expression analysis was performed on the Nano String nCounter platform. A custom code set of a 41-gene panel involved in the DNA damage repair (DDR) and immune response pathways was used. Lasso and elastic net penalized logistic regression were performed to identify a predictive signature. Calculation of the area under the ROC curve (AUC) was used to assess the predictive ability of the signature.

Results

A nine-gene RNA expression signature (RAD51, CXCL9, PARP, 53BP1, HERC2, ERCC2, CHEK1, Ku80 and RNF 168 genes) was associated with pathologic response. The highest predictive ability was observed with the integrated clinical-taxonomical-RNA signature with an AUC of 0.66, in comparison to the clinical-taxonomical classification (AUC=0.58) or the clinical signature alone (AUC=0.52). Furthermore, the integrated signature was significantly associated with overall survival (p = 0.013).

Conclusions

We have identified a nine-gene RNA expression signature that can help to predict response in MIBC patients treated with NAC. Prospective studies are warranted to validate these results.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

AECC.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.